Akonni Biosystems

Akonni Biosystems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.8M

Overview

Akonni Biosystems is a privately held, commercial-stage molecular diagnostics company founded in 2003. It has established itself with a proprietary sample preparation technology, the TruTip system, which provides an alternative to traditional spin columns and magnetic beads for nucleic acid purification. The company operates from a state-of-the-art 20,000 sq. ft. manufacturing facility and serves research and diagnostic markets. Its business model is centered on selling consumable kits and integrated systems, positioning it in the growing sample prep and infectious disease diagnostics sectors.

Infectious Disease

Technology Platform

Patented TruTip pipette-tip technology for solid-phase nucleic acid extraction and purification, designed for high yield and purity, and compatibility with automation.

Funding History

2
Total raised:$14.8M
Series B$12M
Grant$2.8M

Opportunities

Growing demand for efficient, automatable sample prep in genomics and diagnostics presents a significant market.
The need for high-purity nucleic acid for sensitive NGS and PCR assays aligns with TruTip's strengths.
Expansion into integrated, sample-to-answer diagnostic systems for infectious diseases offers a path to higher-margin markets.

Risk Factors

Intense competition from large, established players in the sample prep and diagnostics markets.
Technological obsolescence risk if newer extraction methods emerge.
Regulatory and commercialization challenges associated with bringing integrated diagnostic systems to market.

Competitive Landscape

Akonni competes in the nucleic acid extraction market against giants like Qiagen (spin columns), Thermo Fisher Scientific (magnetic beads), and Roche, as well as numerous smaller firms. Its differentiation is based on claimed superior purity and cost-effectiveness versus columns and beads. In diagnostics, it would face competition from fully integrated MDx systems from companies like Cepheid, BioFire, and Abbott.